The European Commission has granted marketing authorisation (MA) for bemfola, a recombinant follicle-stimulating hormone used for the treatment of infertility. bemfola has been developed by Finox Biotech, a Swiss pharmaceutical company located in Burgdorf. Finox Biotech was founded in 2007 with a vision to develop high-quality Swiss medicines with innovative delivery devices in the field of fertility therapies. We have supported Finox Biotech with all its competencies to establish the brand in a market dominated by large pharmaceutical companies.
Now Finox has achieved a major milestone: The marketing authorisation allows for the marketing of bemfola in all of the 31 countries of the European Union and European Economic Area. And to make things even better – when the good news regarding marketing authorization was received the new Finox Biotech website went live.